Compare Bristol-Myers Squibb Co (BMY) vs Direxion Daily CSI China Internet Bull 2X Shares (CWEB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Direxion Daily CSI China Internet Bull 2X Shares — how do they compare? Bristol-Myers Squibb Co trades at $56.99 (market cap $116.30B), while Direxion Daily CSI China Internet Bull 2X Shares trades at $22.3. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while Direxion Daily CSI China Internet Bull 2X Shares pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Direxion Daily CSI China Internet Bull 2X Shares nearer its low. Which is the better fit depends on your goals.
| BMY | CWEB | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $62.37 | $60.13 |
52-Week Low | $42.60 | $17.70 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
CWEB trades at $21.61, down 1.46% today, with technical indicators showing a bullish bias from moving averages but a neutral stance from oscillators. The stock lacks recent fundamental data, with key valuation and profitability ratios unavailable. A dividend of $0.09 is scheduled for June 2026, indicating a potential income component.
The outlook is mixed due to incomplete financials; technical strength offers near-term upside potential, but investment decisions require updated earnings and revenue figures. Risks include data gaps and market volatility, warranting caution until fundamental clarity emerges from SEC filings or company announcements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Direxion Daily CSI China Internet Bull 2X Shares
CWEB is a leveraged ETF that seeks to provide two times (2x) the daily performance of the CSI China Internet Index. It offers magnified exposure to top Chinese internet companies listed on US and Hong Kong exchanges.
Read more on CWEB →
